Global Idiopathic Pulmonary Fibrosis (IPF) Market Spotlight 2019-2027: Roche’s Esbriet and Boehringer Ingelheim’s Ofev are the only approved drugs for IPF - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Nov 4, 2019--
The “Market Spotlight: Idiopathic Pulmonary Fibrosis (IPF)” report has been added to ResearchAndMarkets.com’s offering.
This Market Spotlight report covers the Idiopathic Pulmonary Fibrosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, 10-year disease incidence and prevalence forecasts, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Topics Covered:
RECENT EVENTS AND ANALYST OPINION
KEY UPCOMING EVENTS
KEY REGULATORY EVENTS
PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
CLINICAL TRIAL LANDSCAPE
For more information about this report visit https://www.researchandmarkets.com/r/3wc14t
View source version on businesswire.com:https://www.businesswire.com/news/home/20191104005337/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH GENERAL HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 11/04/2019 05:12 AM/DISC: 11/04/2019 05:12 AM